Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. 

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Immunology – (ozanimod) Multiple Sclerosis 22-Nov-21 3-Jan-22 14-Jan-22
Immunology – (abatacept)  1-Nov-21 13-Dec-21 14-Jan-22
Immunology – (ozanimod) Ulcerative colitis 1-Nov-21 1-Nov-21 24-Dec-21
Immunology – TYK2 (deucravacitinib) 20-Sep-21 18-Oct-21 19-Nov-21
Oncology – Relatlimab 15-Sept-21  4-Oct-21 29-Oct-21
Hematology 28-May-21 21-Jun-21 23-July-21
Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy 10-May-21 14-Jun-21 9-Jul-21

 


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here

Zeposia (ozanimod) ISR Areas of Interest RFP#1 - 2022: Multiple Sclerosis

 

In Scope:

Individuals with relapsing forms of MS (includes RIS, CIS, RRMS, active SPMS)

  • Early treatment, including clinical benefits, treatment sequencing, response predictors
  • Differentiation among available DMTs, including MS DMT comparisons and patient reported outcomes
  • Management of ethnically and racially diverse patient population and/or MS comorbidities
  • COVID-19 vaccine response/clinical outcomes
  • Brain atrophy & cognition, including correlation of cognition and imaging, clinical relevance and patient centric approaches, cognitive phenotyping
  • Artificial intelligence, in silico and/or digital biomarker models
  • Central effects, including, axonal integrity/astrocyte biology

Out of scope:

  • Pediatric studies
  • Non-approved indications
  • Combination with other disease modifying therapies
  • Alternative dosing other than 0.92 mg QD

IMM- Orencia (abatacept) ISR Areas of Interest – 2021 RFP Cycle 2

 
  • Early Rheumatoid Arthritis – Orencia
    • How to define early Rheumatoid Arthritis
    • How to define early intervention criteria 
  • Biomarker defined Rheumatoid Arthritis and Precision Medicine– Orencia 
    • Predictive and prognostic biomarkers
    • Therapeutic risk benefit profiles:
      • Efficacy and onset of action
      • Long-term treatment: durability of response, safety
  • Rheumatoid Arthritis co-morbidities – Orencia 
    • RA associated with cardio-vascular disease
      • Therapeutic risk benefit profiles 
      • Predictive biomarkers
  • Multi-organ high unmet medical need diseases – Orencia
    • Rheumatologic diseases associated with Rheumatoid Arthritis and/or Auto-antibodies and T cell mediated diseases

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application